The US Food and Drug Administration (FDA) has approved Lenacapavir, a new injectable drug for HIV prevention that costs a staggering K47 million per person per year. The drug, which only requires two injections annually, has also been endorsed by the World Health Organization (WHO) and is set to roll out globally, including in countries like South Sudan.
Health experts are calling it a breakthrough in reducing HIV infections and replacing daily ARV pills, but its high price has sparked concern among advocates pushing for affordability in low-income nations. Pressure is now mounting on Gilead Sciences, the manufacturer, to slash the cost and make the drug accessible to all.